JP2018538309A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538309A5 JP2018538309A5 JP2018532040A JP2018532040A JP2018538309A5 JP 2018538309 A5 JP2018538309 A5 JP 2018538309A5 JP 2018532040 A JP2018532040 A JP 2018532040A JP 2018532040 A JP2018532040 A JP 2018532040A JP 2018538309 A5 JP2018538309 A5 JP 2018538309A5
- Authority
- JP
- Japan
- Prior art keywords
- once
- weeks
- pharmaceutical composition
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15200281.2 | 2015-12-15 | ||
| EP15200281 | 2015-12-15 | ||
| EP16306537 | 2016-11-22 | ||
| EP16306537.8 | 2016-11-22 | ||
| PCT/EP2016/081286 WO2017103003A1 (en) | 2015-12-15 | 2016-12-15 | Anti-cd28 humanized antibodies formulated for administration to humans |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538309A JP2018538309A (ja) | 2018-12-27 |
| JP2018538309A5 true JP2018538309A5 (enExample) | 2020-01-30 |
| JP6923528B2 JP6923528B2 (ja) | 2021-08-18 |
Family
ID=57737702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532040A Active JP6923528B2 (ja) | 2015-12-15 | 2016-12-15 | ヒトへの投与のために処方された抗ｃｄ２８ヒト化抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20180215824A1 (enExample) |
| EP (2) | EP3390450B1 (enExample) |
| JP (1) | JP6923528B2 (enExample) |
| KR (2) | KR20180087428A (enExample) |
| CN (1) | CN108699148A (enExample) |
| CY (1) | CY1124141T1 (enExample) |
| DK (1) | DK3390450T3 (enExample) |
| ES (1) | ES2862395T3 (enExample) |
| HR (1) | HRP20210445T1 (enExample) |
| HU (1) | HUE053736T2 (enExample) |
| LT (1) | LT3390450T (enExample) |
| PL (1) | PL3390450T3 (enExample) |
| RS (1) | RS61958B1 (enExample) |
| SI (1) | SI3390450T1 (enExample) |
| SM (1) | SMT202100185T1 (enExample) |
| WO (1) | WO2017103003A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011101791A1 (en) * | 2010-02-18 | 2011-08-25 | Tcl Pharma | Anti-cd28 humanized antibodies |
| KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| EP4380604A1 (en) | 2021-08-05 | 2024-06-12 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| JP2024534910A (ja) | 2021-09-03 | 2024-09-26 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｌａｍｐ１抗体およびその使用 |
| CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| EP4482865A1 (en) * | 2022-02-24 | 2025-01-01 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004032969A1 (en) * | 2002-10-09 | 2004-04-22 | Lorantis Limited | Modulation of immune function |
| US7651855B2 (en) * | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
| CN100376599C (zh) * | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| US20110097339A1 (en) * | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| WO2011101791A1 (en) * | 2010-02-18 | 2011-08-25 | Tcl Pharma | Anti-cd28 humanized antibodies |
| HUE065915T2 (hu) * | 2011-03-11 | 2024-06-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásaik |
| KR101941004B1 (ko) * | 2013-03-25 | 2019-01-23 | 주식회사 엘지화학 | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 |
-
2016
- 2016-12-15 HR HRP20210445TT patent/HRP20210445T1/hr unknown
- 2016-12-15 EP EP16822423.6A patent/EP3390450B1/en active Active
- 2016-12-15 WO PCT/EP2016/081286 patent/WO2017103003A1/en not_active Ceased
- 2016-12-15 KR KR1020187020218A patent/KR20180087428A/ko not_active Ceased
- 2016-12-15 LT LTEP16822423.6T patent/LT3390450T/lt unknown
- 2016-12-15 PL PL16822423T patent/PL3390450T3/pl unknown
- 2016-12-15 HU HUE16822423A patent/HUE053736T2/hu unknown
- 2016-12-15 EP EP21150940.1A patent/EP3868785A1/en active Pending
- 2016-12-15 ES ES16822423T patent/ES2862395T3/es active Active
- 2016-12-15 CN CN201680080258.4A patent/CN108699148A/zh active Pending
- 2016-12-15 SI SI201631115T patent/SI3390450T1/sl unknown
- 2016-12-15 RS RS20210451A patent/RS61958B1/sr unknown
- 2016-12-15 KR KR1020247030946A patent/KR20240144440A/ko active Pending
- 2016-12-15 SM SM20210185T patent/SMT202100185T1/it unknown
- 2016-12-15 JP JP2018532040A patent/JP6923528B2/ja active Active
- 2016-12-15 DK DK16822423.6T patent/DK3390450T3/da active
-
2018
- 2018-03-12 US US15/918,699 patent/US20180215824A1/en not_active Abandoned
-
2019
- 2019-10-24 US US16/662,399 patent/US20200115453A1/en not_active Abandoned
-
2021
- 2021-04-16 CY CY20211100337T patent/CY1124141T1/el unknown
-
2022
- 2022-02-10 US US17/668,969 patent/US20220411510A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,454 patent/US20250051446A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538309A5 (enExample) | ||
| Vincenti et al. | What’s next in the pipeline | |
| Kuhn et al. | Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside | |
| IL274595B2 (en) | Antibodies specific to beta-tgf | |
| JP2017079785A5 (enExample) | ||
| RU2009149462A (ru) | АНТИТЕЛА ПРОТИВ NRR Notch1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| Taylor et al. | Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions | |
| RU2013148590A (ru) | Способы введения антагонистов интегрина бета7 | |
| Park et al. | Updated treatment strategies for intestinal Behçet’s disease | |
| Campochiaro et al. | Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis | |
| Papagoras et al. | Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis | |
| Geng et al. | Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19 | |
| Mazza et al. | Innovative uses of tumor necrosis factor α inhibitors | |
| HRP20210445T1 (hr) | Humanizirana protutijela anti-cd28 koja su formulirana za primjenu na ljudima | |
| Markatseli et al. | Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study | |
| JPWO2020254827A5 (enExample) | ||
| Neogi | IL-1 antagonism in acute gout: Is targeting a single cytokine the answer? | |
| JP2017501999A5 (enExample) | ||
| JP2019508448A5 (enExample) | ||
| Uthman | Pharmacological therapy of vasculitis: an update | |
| Comarmond et al. | Approaches to Immunosuppression in Behçet‘s Disease | |
| JP2015511588A5 (enExample) | ||
| Sharma et al. | ANCA-associated vasculitis | |
| Heemann et al. | The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents | |
| JP2005529152A5 (enExample) |